Shares in Clinuvel Pharmaceuticals Ltd (ASX: CUV) climbed around 5% to $10.40 on Monday after the ASX biotech stock confirmed its shares will begin trading on the Nasdaq stock exchange in the US.
The Nasdaq is the world’s second-largest stock exchange after the New York Stock Exchange. It is home to many of the world’s leading technology and healthcare companies, including Nvidia Corp (NASDAQ: NVDA) and Microsoft Corp (NASDAQ: MSFT).
Clinuvel confirms Nasdaq debut
In an ASX announcement today, the ASX biotech stock said its American Depositary Shares (ADS) are expected to commence trading on the Nasdaq later on Monday (New York time) under the ticker CUVL.
The milestone follows the US Securities and Exchange Commission declaring the company’s Form 20-F registration statement effective on 17 July, along with Nasdaq approving the listing.
As part of the move, Clinuvel’s existing over-the-counter American Depositary Receipt (ADR) program will be upgraded from a Level I ADR to a Level II ADS listed on Nasdaq. Each ADS will represent one ordinary Clinuvel share listed on the ASX.
Importantly, the company is not raising capital or issuing new shares as part of the listing. This means the move is designed to improve market access rather than fund the business.
Existing holders of Clinuvel’s US-traded ADRs also won’t need to take any action. Their holdings will automatically transition to the new Nasdaq-listed security.
Why does a Nasdaq listing matter?
A Nasdaq listing can significantly increase a company’s visibility among US investors and improve trading liquidity. It also provides access to specialist healthcare and biotechnology investors who are often more familiar with the sector and can broaden the company’s shareholder base.
The Nasdaq Global Select Market, where the ASX biotech stock will trade, also offers greater analytical coverage and inclusion in Nasdaq’s market ecosystem. This potentially increases awareness among institutional investors.
That said, investors shouldn’t expect the listing alone to transform the company’s fortunes overnight. Greater visibility could support future growth opportunities and provide access to deeper capital markets if required. However, Clinuvel’s long-term success will ultimately depend on executing its commercial strategy.
What did management say?
Clinuvel Chairman Jeffrey Rosenfeld said:
The upgrade of CUVL to the Nasdaq marks an important step for Clinuvel’s visibility in U.S. capital markets, as well as reflecting a broader shift of our business towards North America. In the context of all our activities, the gradual shift to the U.S. makes much sense as the Company is maturing.
Foolish Takeaway
Clinuvel already has a commercialised product in SCENESSE®. It is approved in multiple markets, including the United States and Europe.
The Nasdaq listing has the potential to raise the international profile of the ASX biotech stock. It also expands its access to one of the world’s deepest pools of healthcare capital.
However, the real driver of long-term shareholder returns will remain business execution.
Despite today’s rally, Clinuvel shares are still down around 17% so far this year. This suggests investors are waiting for stronger evidence that the company’s next phase of growth is taking shape.
The post This ASX biotech stock just scored a Nasdaq listing. Shares are jumping appeared first on The Motley Fool Australia.
Should you invest $1,000 in Clinuvel Pharmaceuticals right now?
Before you buy Clinuvel Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Clinuvel Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Microsoft and Nvidia. The Motley Fool Australia has recommended Microsoft and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.